Navigation Links
Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer
Date:11/5/2009

ROCHESTER, N.Y., Nov. 5 /PRNewswire-USNewswire/ -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice. While key experiments were in animals, the cancer studied closely resembled the human form and the drug has already been proven to be safe in human patients.

In the current study, researchers sought to use Bortezomib (Velcade(R)) against osteosarcoma, an aggressive cancer that starts in bone, spreads quickly and responds poorly to current chemotherapies. The drug, a proteasome inhibitor developed by Millennium Pharmaceuticals and Johnson & Johnson, was approved by the FDA for the treatment of a rare, aggressive form of non-Hodgkin's lymphoma in 2006 and for multiple myeloma in 2008.

"Our most clinically relevant finding is that a drug already proven safe and effective in treating the most common cancers of the blood may be equally effective in suppressing bone cancer," said Roman Eliseev, M.D., Ph.D., research assistant professor within the Center for Musculoskeletal Research and the James P. Wilmot Cancer Center, both within the University of Rochester Medical Center. "Bortezomib caused osteosarcoma cells to self destruct, and prevented their spread. While further studies are needed, our findings suggest that this drug may represent a new treatment option for a devastating disease and an effective complement to current chemotherapies."

Reason to Hope

Eliseev's lab and others have shown that a protein complex called Runx2 both blocks the growth of bone cancer cells and triggers a quality control mechanism that causes abnormal cells to self-destruct. For some reason, however, Runx2 levels are dramatically reduced in bone cancer cells.

In the current study, researchers found that Bortezomib shuts down cellular machines that destroy Runx2, machines that become overactive in bone cancer patients. Bortezomib restored Runx2 levels in osteosarcoma cell lines and in osteosarcoma tumors in mice. In addition, tests found a three-fold increase in the bortezomib-treated group in the number of cancer cells testing positive for an enzyme (caspase-3) known to drive them to self-destruct. Experiments also showed that the average size of osteosarcoma tumors in bortezomib-treated mice was only 30 percent of that in the control group.

The new findings also provide the first explanation of why Runx2 levels are lower in bone cancer cells. Researchers found that Runx2, which encourages abnormal cells to self destruct, may itself become the target of cellular machines called proteosomes that break down and recycle unneeded proteins.

Specifically, the team found in osteosarcoma cells high levels of a protein called Smurf1, known to tag aging proteins for attention by protein-devouring proteosomes. The team is now looking at why levels of Smurf1 are higher in osteosarcoma. In addition, Eliseev and colleagues plan to launch a pilot study later in 2010 using bortezomib to treat osteosarcoma.

Along with Eliseev, the work was led by Yuriy Shapovalov, David Benavidez and Daniel Zuch within the Center for Musculoskeletal Research at the Medical Center. The study was funded in part by the Karen D'Amico Foundation, the James P. Wilmot Foundation and the National Institutes of Health.

"These data argue that bortezomib treatment not only caused bone cancer cells to signal for their own self-destruction, but also suppressed the ability of osteosarcoma cells to grow, in a two-fold effect," Eliseev said. "The study results also give us reason to hope that the treatment will avoid side effects, because bortezomib induces cell death in osteosarcoma cells but not in normal bone-making cells."

SOURCE University of Rochester Medical Center


'/>"/>
SOURCE University of Rochester Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
2. Minimally Invasive Device Approved to Treat Liver Cancer, Fibroids, Tumors, and Bleeding
3. FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets
4. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
5. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
6. United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
7. ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
8. Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
9. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
10. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
11. Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):